Understand the source comparison
Best Research Peptides for Ligament Tear: Mechanism Comparison
BPC-157 Growth hormone receptor activation in fibroblasts; upregulates FAK-paxillin pathway for cell migration and ECM remodelling Proliferative phase (days 7–21) 250–500mcg daily subcutaneous Human clinical trial data absent; dosing extrapolated from rodent a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Growth hormone receptor activation in fibroblasts; upregulates FAK-paxillin pathway for cell migration and ECM remodelling
- Proliferative phase (days 7–21)
- 250–500mcg daily subcutaneous
- Human clinical trial data absent; dosing extrapolated from rodent allometric scaling
- Strongest preclinical evidence for tendon-to-bone healing; most relevant for intra-articular ligament injuries
- TB-500
- VEGF upregulation; angiogenesis in hypovascular tissue; reduces fibrotic scar formation
- Proliferative through early remodelling (days 7–35)
- 2–5mg weekly subcutaneous, loading phase 2×/week
- Equine veterinary data; human use is anecdotal self-administration
- Best suited for ligaments with poor baseline vascularity (ACL, meniscal attachments)
- GHK-Cu
- Copper-dependent collagen stabilisation; promotes organised triple-helix formation; anti-inflammatory via TGF-β modulation
- Late proliferative through remodelling (days 14–90+)
- 1–3mg daily subcutaneous or topical
- Wound-healing studies focus on dermal tissue; ligament-specific data limited
- Most useful during late-stage remodelling to prevent disorganised scar tissue